carbamates has been researched along with Myeloproliferative Disorders in 3 studies
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganai, SA | 1 |
| Amaru Calzada, A | 2 |
| Todoerti, K | 1 |
| Donadoni, L | 1 |
| Pellicioli, A | 1 |
| Tuana, G | 1 |
| Gatta, R | 1 |
| Neri, A | 1 |
| Finazzi, G | 2 |
| Mantovani, R | 1 |
| Rambaldi, A | 2 |
| Introna, M | 2 |
| Lombardi, L | 1 |
| Golay, J | 2 |
| Pedrini, O | 1 |
| Leoni, F | 1 |
| Mascagni, P | 1 |
1 review available for carbamates and Myeloproliferative Disorders
| Article | Year |
|---|---|
Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
Topics: Antineoplastic Agents; Carbamates; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Hodgkin Di | 2016 |
2 other studies available for carbamates and Myeloproliferative Disorders
| Article | Year |
|---|---|
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Topics: Carbamates; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Histone Deace | 2012 |
Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.
Topics: Amino Acid Substitution; Antineoplastic Agents; Apoptosis; Blotting, Western; Carbamates; Caspase 3; | 2013 |